Veliparib is a new oral drug that is being developed for patients with HER2- breast cancer that is advanced and cannot be removed completely through surgery. The drug acts by targeting specific enzymes involved in the repair of damaged DNA that helps the body to kill cancer cells while allowing ordinary cells to survive. Veliparib is being developed to be used in combination with the chemotherapy drugs paclitaxel and carboplatin. If licenced, this combination will offer an additional treatment option for patients with HER2- metastatic or locally advanced unresectable BRCA-associated breast cancer.
Paclitaxel formulated as albumin bound nanoparticles (Nab-paclitaxel) in combination with gemcitabine is being developed as a treatment option for patients with pancreatic cancer who have undergone surgery to increase the chances of being cured (‘adjuvant therapy’). Both drugs are chemotherapies already being used to treat metastatic pancreatic cancer and other types of cancers and are administered by injection.